Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
59 results about "Tumor cytotoxicity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Hypoxia and Reduced T Cell Cytotoxicity in Tumors. A hypoxic environment is a common characteristic of tumors for many cancers. The lower level of oxygen reduces the immune response surrounding the tumor (immunogenicity) by attracting regulatory T cells and reducing the ability of other T cells.
Method for efficiently multiplying gamma delta T cells by stimulating peripheral blood in vitro and application of method
ActiveCN105112370AIntact Antitumor CytotoxicityMammal material medical ingredientsBlood/immune system cellsWhite blood cellAntigen receptors
The invention belongs to the field of medical biology engineering, and particularly relates to a method for effectively multiplying gamma delta T cells by stimulating peripheral blood in vitro and application of the method. The method comprises the step of using feeder cells, an OKT3 (ornithine ketoacid transaminase) antibody, interleukin-2 and zoledronic acid. The feeder cells are formed by specifically inserting CD64, CD86 and CD137L genes in a target site of a genome of the feeder cells. After the zoledronic acid and the nterleukin-2 are used for increasing the proportion of the gamma delta T cells of the peripheral blood, protein products of genes, the OKT3 antibody and the interleukin-2 act in a combined manner, and the gamma delta T cells can be stimulated so that a large amount of gamma delta T cells can be multiplied. The multiplied gamma delta T cells can be used for killing tumor cells which are pretreated by the zoledronic acid, or the tumor cells can be directly killed by modifying and expressing chimeric antigen receptors (CAR) via a genetic engineering means. The gamma delta T cells which are obtained by the method have complete anti-tumor cytotoxicity, and can kill solid tumor cells and non-solid tumor cells.
Owner:杭州朔溪生物医药有限公司
Use of PARP-1 Inhibitors
InactiveUS20090170860A1Good effectStrong cytotoxicityBiocideAnimal repellantsTumor cytotoxicityWilms' tumor
A method for improving the cytotoxic effect of Ecteinascidin-743 (ET-743) or an analog thereof on a tumor cell population in a patient the method including administering to the patient, sequentially or simultaneously, a therapeutically effective combination of a composition including ET-743 and an amount of a composition including a PARP-1 inhibitor effective to increase the cytotoxic effect of ET-743 on the tumor cell population. Anti-tumor compositions containing a therapeutically effective amount of ET-743 and an amount of a PARP-1 inhibitor effective to increase the tumor cytotoxicity of the ET-743 are also presented.
Owner:PHARMA MAR U
Composition with anti-tumor effect and application thereof in preparing medicament for treating tumor
InactiveCN101822832AImprove anti-tumor effectReduce cardiotoxicityAmphibian material medical ingredientsOrganic active ingredientsAntiarrhythmic effectToad Venom
The invention provides a composition with anti-tumor effect and application thereof. The composition consists of 0.01 to 10 weight parts of pure bufadienolide compound, extract rich in bufadienolide compound, raw toad venom or toad skin and 0.01 to 99.9 weight parts of medicament with anti-arrhythmic effect. The composition with the anti-tumor effect has the advantage that the match among the components is scientific and reasonable; multiple in vitro tumor cytotoxicity and in vivo tumor inhibiting experiments show that the composition provided by the invention has good anti-tumor effect and plays a role in synergy after combination; and cardiotoxic experiments show that the cardiotoxicity of the composition provided by the invention is obviously reduced, and the composition can reduce the cardiotoxicity caused by primary single use of the bufadienolide compound, the toad venom or the toad skin and plays a role in detoxifying. Therefore, the composition is safer and more effective to use, and is expected to develop a new generation anti-cancer medicament.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Culture method of tumor specific TIL cells
InactiveCN105087485AEfficient ProliferationImprove tumor killing abilityBlood/immune system cellsSerum freeMagnetic bead
The invention belongs to the field of biomedical detection, and in particular relates to a culture method of tumor specific TIL cells. According to the culture method of the tumor specific TIL cells disclosed by the invention, the tumor specific TIL cells can be acquired by screening specific magnetic beads twice. The method disclosed by the invention is simple in operation, and is capable of efficiently obtaining the tumor specific TIL cells through multiplication culture and greatly enhancing the tumor-cytotoxicity effect of the TIL cells; and meanwhile, through serum-free culture, the method can solve the potential risks of transmission of viruses and other dangers in the prior art, so as to provide a foundation for extensive application in the future.
Owner:SHANGHAI XINCHEN MEDICAL TECH CO LTD
Preparation method of effective part of dendrobium officinale
ActiveCN104258106AOvercome the shortcoming of extremely low extraction rate of fat-soluble active ingredientsImprove utilization efficiencyAntinoxious agentsAntineoplastic agentsHigh concentrationBULK ACTIVE INGREDIENT
The invention discloses a preparation method of an effective part of dendrobium officinale. The method comprises steps as follows: firstly, extracting fat-soluble extracts represented by bibenzyl from the dendrobium officinale with a high-concentration alcohol-water system, refining the extracts with a macroporous resin method to obtain a total bibenzyl effective part with the bibenzyl content higher than 50%, and preparing dregs of the extracts into dendrobium officinale total polysaccharides with water extraction and alcohol precipitation methods; drying and evenly mixing the total bibenzyl effective part and the dendrobium officinale total polysaccharides obtained in two steps to obtain a dendrobium officinale total effective part extract. According to the method, the defect of the extremely low extraction rate of dendrobium officinale fat-soluble active ingredients represented by the bibenzyl with traditional methods such as a water decoction method, a tea making method and the like is overcome, the utilization efficiency of the effective part of the dendrobium officinale is improved substantially, pharmacological anti-oxidation animal experiments and anti-tumor cytotoxicity experiments prove that the activity of the effective part is significantly higher than that of traditional aqueous extracts, and the effective part has the characteristics of high extraction rate and high activity.
Owner:NINGBO FENGKANG BIOLOGICAL TECH
Tumour Cytotoxic Agent and Methods Thereof
The present invention discloses a novel antitumour agent which provides an antitumour activity based on metabolites with reduced side effects. Moreover, the antitumour agent is prepared starting with a highly safe bacterium used in food production, which is a probiotic lactic acid bacterium.
Owner:UNIVERSITI PUTRA MALAYSIA
Sulfur-substituted podophyllum derivative and bioconversion, separation and purification method thereof
InactiveCN102757443ACultivableHas supplyOrganic active ingredientsOrganic chemistryPurification methodsSulfur
The invention discloses a sulfur-substituted podophyllum derivative and a bioconversion, separation and purification method thereof. The sulfur-substituted podophyllum derivative with antitumor activity, shown as Formula (I) or (II), is obtained by modifying the molecular structure of podophyllotoxin or 4'-demethylepipodophyllotoxin through a bioconversion method. Preliminary study on in-vitro tumor cytotoxicity shows that the sulfur-substituted podophyllum derivative disclosed by the invention has stronger inhabitation action on the growth of tumor cells such as BGC823, HepG2, A549 and the like, and thus can be used as an antitumor compound to achieve a potential drug development value. According to the invention, the podophyllotoxin and the 4'-demethylepipodophyllotoxin are converted into the sulfur-substituted podophyllum derivative by using a bioconversion method, and therefore, the sulfur-substituted podophyllum derivative has the advantages of low cost and E-factor, simplicity in operation, easiness for culturing, controllable quality, capability of effectively preventing chemical residuals and the like.
Owner:HUBEI UNIV OF TECH
Method of expanding nk cell and composition for culturing
InactiveUS20170119865A1Increase the number of cellsEfficiently obtainedHydroxy compound active ingredientsCulture processP53 proteinTumor cytotoxicity
Provided are a method of ex-vivo culture of natural killer (NK) cells by treating the cells with a reactive oxygen species (ROS) inhibitor and / or a p53 protein inhibitor; and a composition comprising the cultured NK cells. By reducing the activity of ROS and p53 proteins during ex-vivo culture, NK cells may have achieved greater expansion efficiency without altering their anti-tumor cytotoxicity.
Owner:KOREA UNIV RES & BUSINESS FOUND
Preparation method of high-efficiency killer cell preparation adopting immunodetection point dual-block CTL (cytotoxic lymphocyte)
ActiveCN106177931AReduce exhaustEnhance tumor killing effectCancer antigen ingredientsBlood/immune system cellsTumor specificInterleukin 4
The invention discloses a preparation method of a high-efficiency killer cell preparation adopting an immunodetection point dual-block CTL (cytotoxic lymphocyte). The preparation method comprises steps as follows: step 1), collecting mononuclear cells in peripheral blood; step 2), performing DC (dendritic cell) separation and T cell separation on the separated mononuclear cells with an adherence method; step 3), adding adhering DCs to a serum-free culture medium containing GM-CSF (granulocyte-macrophage colony-stimulating factor) and IL-4 (interleukin-4) for preparation of a DC vaccine; step 4), adding suspending T cells to CD3 and IL-2 for T cell culture and amplification; step 5), adding antigen-supported DCs to the amplified T cells for preparation of the CTL, and adding PD-1 (Programmed death 1) and CTLA-4 (cytotoxic t lymphocyte associated antigen-4) antibodies for preparation of the cell preparation with the dual-block CTL effect. According to the novel technology and the novel method provided by the invention, an immune brake effect is effectively regulated and T cell depletion is retarded by blocking inhibitory molecules on the tumor specific CTL surfaces, so that the tumor cytotoxicity of CTL effector cells is substantially improved.
Owner:浓孚雨医药河北有限公司
Plasmid structure for expressing CD19CAR and knocking down T cell surface PD-1 expression simultaneously and construction method thereof
InactiveCN108424927ALow efficiencyEnhanced killing effect in vitroVector-based foreign material introductionHinge regionWilms' tumor
The invention relates to a plasmid structure for expressing CD19CAR and knocking down T cell surface PD-1 expression simultaneously. The plasmid structure comprises an H1 promoter, an anti-PD-1shRNA sequence started by the H1 promoter, an EF1alpha promoter and a three-generation CD19CAR sequence started by the EF1alpha promoter that are connected in series in order. The three-generation CD19CAR sequence consists of a CD19 single chain variable region, a human CD8alpha hinge region, a human CD28 transmembrane region and an intracellular region, a human 41BB intracellular region and a human CD3zeta intracellular region that are connected in series. The plasmid structure provided by the invention is transduced into T cells by a lentivirus, and the CART cell production process is significantlysimplified than using CRISPR / Cas9 for knockout of PD-1. Moreover, the CART cells show enhanced tumor cytotoxicity killing ability and increased persistent cell repair and cytokine secretion ability after antigenic stimulation in vitro.
Owner:WUHAN BIO RAID BIOTECH CO LTD
Method for treating tumor and/or preventing tumor metastasis and relapse
InactiveUS20060148681A1Preventing tumor metastasisSaccharide peptide ingredientsAntineoplastic agentsAbnormal tissue growthLymphatic Spread
The present invention provides a method for treating tumor and / or preventing tumor metastasis and relapse comprising administrating a subject with a therapeutically effective amount of lectin capable of binding to the tumor and having tumor cytotoxicity and / or lymphocyte activation activity.
Owner:NAT CHENG KUNG UNIV
Application of eudesmane sesquiterpene lactone epimers in preparation of anti-breast cancer medicine
The invention discloses a pair of eudesmane sesquiterpene lactone epimers (1S,4S,5S,6S,7S,8S,9R,10S)-1,9-diacetoxy-4-hydroxy-6-isobutyryloxyprostatolide and (1S,4S,5R,6S,7S,8S,9R,10S)-1,9-diacetoxy-4-hydroxyl-6-isobutyryloxyprostatolide, pharmaceutically acceptable salts or solvates of the epimers, and pharmacodynamic activity of a pharmaceutical composition composed of the compounds, and mainly relates to a medical application of an anti-breast cancer medicine in inducing breast cancer cell MCF-7 cell morphology to retract and become round and the level of intracellular reactive oxygen species (ROS) to rise to show tumor cytotoxicity.
Owner:HAINAN NORMAL UNIV
Application of hemsley rockvine root extract in preparing tumor immunity therapeutic drug and human gamma delta T cell proliferation agent
InactiveCN106421184APromote proliferationEnhance killing activityBlood/immune system cellsAntineoplastic agentsHigh concentrationT cell
The invention relates to application of a hemsley rockvine root extract in preparing a tumor immunity therapeutic drug and a human gamma delta T cell proliferation agent, belonging to the technical field of medicine and biology. The hemsley rockvine root extract can notably accelerate proliferation of human gamma delta T cells, improves the expressions of porforin, CD107a and granzyme B of the gamma delta T cells, and has certain dose dependence; and the gamma delta T cells treated by the hemsley rockvine root extract can apparently improve the tumor-cytotoxicity activity of the gamma delta T cells and have certain dose dependence. A high-concentration hemsley rockvine root extract can inhibit the growth of tumor cells. The invention initially discovers that a low-concentration hemsley rockvine root extract can notably promote proliferation of the human gamma delta T cells; the low-concentration hemsley rockvine root extract can promote expressions of the porforin, granzyme B and CD107a of the gamma delta T cells; the cytotoxicity activity of the gamma delta T cells is apparently improved; and different extracted components of the hemsley rockvine root are apparently different in proliferation of the gamma delta T cells.
Owner:浙江博纳生物科技有限公司
c-Myc gene expression inhibitor and application thereof
ActiveCN109820866AStrong cytotoxicityGrowth inhibitionOrganic active ingredientsAntineoplastic agentsWilms' tumorTumor cell apoptosis
The invention discloses a c-Myc gene expression inhibitor, and application thereof to preparing anti-tumor medicines. The c-Myc gene expression inhibitor is a pyrrole-imidazole polyamide small molecule. The pyrrole-imidazole polyamide small molecule is targeted to a c-Myc gene promoter sequence through a recognizing and pairing mode, and the expression of a c-Myc gene is silenced. Polyamide PA6 presents good tumor cytotoxicity, the growth of tumor cells can be restrained, and the apoptosis of the tumor cells is induced.
Owner:ZHEJIANG UNIV OF TECH
Method for cultivating lymph-node autologous CIK (cytokine-induced killer) cells and application of lymph-node autologous CIK cells
InactiveCN105154399AStrong anti-tumor proliferation ability in vitroPrevent proliferationMammal material medical ingredientsBlood/immune system cellsLymphatic SpreadCancer cell
The invention belongs to the field of biotechnology and microbial animal cell lines and particularly relates to a method for cultivating lymph-node autologous CIK (cytokine-induced killer) cells and application of the lymph-node autologous CIK cells. The CIK cells are obtained by in-vitro cultivation of isolated lymph node tissue obtained in surgery in patients with lung cancer and are compared with the CIK cells obtained from cultivation of isolated peripheral blood, biological characteristics of the CIK cells and cytotoxicity effect on pulmonary granule cancer cells are observed, the result shows that the isolated lymph node issue of the surgical patients can be completely used for cultivation of CIK, in-vitro tumor-cytotoxicity cells are powerful in activity, and the activity and cancer inhibition function are prior to the CIK cells of the peripheral blood. The CIK cells can be used for preparing pulmonary granule and cancer inhibition products and made into compounds with chemotherapy drugs as well as used for adoptive immunity and intervention for postoperative patients with lung cancers, and occurrence rate for recurrence and metastasis of the postoperative patients with the lung cancers is beneficially decreased.
Owner:SHANGHAI CHEST HOSPITAL
Orthoester 5-fluorouracil prodrug molecule, preparation method and acid-sensitive nanoparticle and application thereof
ActiveCN109369625AImprove lipophilicityIncrease fat solubilityOrganic active ingredientsOrganic chemistryTarget enrichmentMiscellaneous antineoplastic
The invention discloses an orthoester 5-fluorouracil prodrug molecule. The orthoester 5-fluorouracil prodrug molecule is N-5-fluorouracil1-ethyl-2-carbonalkoxy-(1,3) dioxolane-4-methylformamide havinga structure as shown in formula (I) described in the specification, wherein n=2-32 and m=n+2. The invention further discloses a preparation method of the abovementioned prodrug molecule and a nanoparticle prepared therefrom and an application thereof. The orthoester 5-fluorouracil prodrug molecule, the preparation method and the nanoparticle and the application thereof have the advantages that the nanoparticle prepared by the orthoester 5-fluorouracil prodrug molecule not only has the advantages of a small molecule prodrug but also is endowed with the advantage of a nano drug delivery system(that is a drug carrier), the prodrug nanoparticle not only has excellent acid degradation property and reduced tumor cytotoxicity and realizes passive targeting enrichment of a drug in a tumor, the nanoparticle has high drug loading capacity because the drug is used as a main part of the carrier, and the nanoparticle is capable of loading other antitumor drugs and achieves the effect of cooperatively treating the tumor and thus has good application prospects in the field of tumor treatment.
Owner:ANHUI UNIVERSITY
Antitumor drug based on PGA-RB (Polyglutamic Acid-Rose Bengal) bound compound and preparation method and application of antitumor drug
InactiveCN104491863AGood water solubilityGood tumor targetingPowder deliveryEnergy modified materialsCancer cellBiocompatibility Testing
The invention discloses an antitumor drug based on a PGA-RB (Polyglutamic Acid-Rose Bengal) bound compound and a preparation method and application of the antitumor drug. The structural formula of the antitumor drug is shown as Formula I, wherein the bonding rate of RB is 5-30 percent. According to the invention, RB is modified to obtain an RB derivative, the RB derivative is bound with PGA to obtain the antitumor drug, the antitumor drug can be self-assembled in a water solution into nanometer particles of 100-200 nm, and the nanometer particles have the advantages of high stability, good biocompatibility, long in-vivo circulation time, obviously enhanced toxicity to cancer cells under light, and the like; and the preparation method has simple steps and is convenient to operate.
Owner:ZHEJIANG UNIV
1-(3',4',5'- trisubstituted phenyl)- tetrahydroisoquinoline compound and its use
The invention relates to a 1-(3', 4', 5'-trisubstituted phenyl)-isoquinolin compound with tumor cytotoxicity shown in a formula (1) and intermediate compounds thereof or pharmaceutical salts or solvates thereof, The invention also relates to a method for preparing the compounds in the formula (1), pharmaceutical compositions and medicinal application thereof. The compounds have certain activity of inhibiting growth of tumor cells, and can be expected to be used as anti-tumor drugs. A structural formula (1) of the invention is shown in a figure.
Owner:ZHEJIANG UNIV
Metal organic framework drug-loaded nano system based on small molecule drug
ActiveCN112891548AImprove stabilitySolving Simultaneous Delivery IssuesOrganic active ingredientsPharmaceutical non-active ingredientsMetal-organic frameworkEfficacy
The invention provides a preparation method and application of a metal organic framework drug-loaded nano system based on a small molecule drug, MIT and HYD are jointly loaded in pores of a metal organic framework ZIF-8 through a simple and rapid method to prepare nano particles, and active targeting HA modification of tumor cells is realized. The problems of poor stability of MIT and HYD and co-delivery of MIT and HYD are solved, and the immune efficacy of chemotherapeutic drugs is enhanced. The (M+H) (at) ZIF / HA intravenous injection preparation is low in toxicity, good in safety, high in tumor cell toxicity and obvious in solid tumor inhibition effect.
Owner:SHANDONG UNIV
Biologically active peptide and method for proliferating CIK cell in vitro
ActiveCN106676068AExcellent in vitro tumor killing effectExcellent anti-tumor effect in vivoCulture processCell culture mediaUltrafiltrationVenous blood
The invention discloses a biologically active peptide and a method for proliferating a CIK cell in vitro. The method comprises the following steps: drawing peripheral venous blood, separating a single karyocyte, culturing the single karyocyte in a culture flask pre-coated with the biologically active peptide and an anti-CD3 monoclonal antibody by virtue of a serum-free culture medium, only adding IL-2 and the serum-free culture medium in a culture system afterwards, and performing culturing for 14 to 21 days under the conditions of 37 DEG C and 5% CO2, wherein the biologically active peptide is obtained by performing enzymatic hydrolysis on a raw material cicada with trypsin, entrapping a component of a molecular weight of 3,000 to 1,000u by virtue of an ultrafiltration membrane and performing freeze-drying. The biologically active peptide can be used for efficiently inducing in-vitro proliferation of the CIK cell, high survival rate and high purity are achieved, and the CIK cell obtained by the method for proliferating the CIK cell in vitro has good in-vitro tumor cytotoxicity effects and in-vivo tumor suppression effects; in addition, the biologically active peptide which is low in cost and readily available is used according to the method instead of recombinant human IFN-gamma and IL-1alpha in a conventional culturing method, so that the cost is low.
Owner:杭州鑫生源生物科技有限公司
Immunologic adjuvant functionalized metal organic framework material as well as preparation method and application thereof
ActiveCN112007170AIncreased toxicityExcellent photothermal conversion performancePhotodynamic therapyEchographic/ultrasound-imaging preparationsFluorescenceMetal-organic framework
The invention discloses an immunologic adjuvant functionalized metal organic framework material as well as a preparation method and application thereof. The preparation process comprises the followingsteps: synthesizing MIL-101-NH2, namely MOF, combining ICG with MOF to form MOF-ICG, and loading CpG on MOF-ICG. The material can be applied to preparation of medicines. The material has the advantages that (1) the ultraviolet-visible absorption spectrum peak value of the material provided by the invention is about near-infrared light; the near-infrared laser with single wavelength can be used for exciting photodynamic and photothermal effects at the same time, has excellent singlet oxygen generation capability and photothermal conversion capability under the irradiation of the near-infraredlaser, and has huge application potential in the aspect of tumor phototherapy; (2) in a tumor microenvironment, the material-loaded CpG and TAA released by photodynamic and photothermal therapy jointly activate an immune system, so that the tumor cytotoxicity is enhanced, and the treatment effect is improved; and (3) the material provided by the invention has a tumor multi-modal imaging (fluorescence, photoacoustic, photo-thermal and nuclear magnetic resonance) function, and can be used for monitoring the tumor position and the treatment effect.
Owner:DERMATOLOGY HOSPITAL SOUTHERN MEDICAL UNIV (GUANGDONG PROVINCIAL DERMATOLOGY HOSPITAL GUANGDONG PROVINCIAL CENT FOR STI & SKIN DISEASES CONTROL & PREVENTION RES CENT FOR LEPROSY CONTROL & PREVENTION CHINA)
Tumor cytotoxicity induced by modulators of the CXCR4 receptor
The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and / or intraurethral administration in liquid or particulate form.
Owner:BOND VINCENT C +2
LA-GFLG-DOX conjugate, preparation method and use thereof
ActiveCN110193086AEnhanced inhibitory effectHas antitumor activityOrganic active ingredientsPeptide preparation methodsSide effectOxygen
The invention relates to an antitumor drug, a preparation method and use thereof, which belong to the field of a medicine, and particularly discloses a LA-GFLG-DOX conjugate, a preparation method thereof and use thereof, and the LA-GFLG-DOX conjugate is a compound formed by sequential connection of lipoic acid, glycine, phenylalanine, leucine, glycine, and doxorubicin molecules through an amide bond. The conjugate retains the toxicity of DOX to tumor cells, and utilizes the antioxidant capacity of LA to resist damage to normal cells caused by reactive oxygen produced by DOX. From the anti-tumor activity test and the toxic side effects on normal cells, the LA-GFLG-DOX conjugate has a significant inhibitory effect on tumor cells, can reduce damage to normal cells, and reduces the toxic sideeffects of DOX.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Hyaluronic acid artesunate, nano-micelle preparation of hyaluronic acid artesunate, and preparation method and use of nano-micelle preparation
PendingCN112089690AGood responsive release characteristicsStrong targetingOrganic active ingredientsPowder deliveryBULK ACTIVE INGREDIENTTumor cytotoxicity
The invention discloses hyaluronic acid artesunate, a nano-micelle preparation of hyaluronic acid artesunate, and a preparation method and use of the nano-micelle preparation. The active ingredient hyaluronic acid artesunate consists of artesunate and hyaluronic acid, wherein artesunate serves as a main active ingredient, hyaluronic acid serves as a carrier and a targeting molecule and is connected with artesunate through a chemical bond to form hyaluronic acid artesunate, and then self-assembly is performed to form a nano-micelle and freeze-drying is performed to obtain the nano-micelle preparation. A particle size of the hyaluronic acid artesunate nano-micelle is 100-200 nm, the freeze-dried preparation is good in stability, and has a relatively good acidity responsive release characteristic after being injected into a body, and cytotoxicity tests prove that compared with the artesunate pure medicine, the nano-micelle preparation has stronger tumor cytotoxicity effects. The nano-micelle preparation has the characteristics of strong targeting property, long circulation and low toxicity.
Owner:XIAMEN UNIV
Substituted cinnamic acid derivatives containing amine substituent group and expression purification cytotoxicity thereof
InactiveCN101230015AHas tumor growth inhibitory activityOrganic active ingredientsOrganic chemistryTumor cytotoxicitySquamous carcinoma
The invention relates to a substituted cinnamic acid derivatives comprising amides substituent with a structure shown as Formula (I) and cytotoxic activity as well as medicine salts or solvates of the derivatives. The invention also relates to the preparation method and medicine purpose of the compounds with a Formula (I) The compounds of invention are provided with the activity of inhibiting growth of human oral squamous carcinoma cells, namely KB cell. The derivatives can be expected to be used as an antitumor drug.
Owner:WENZHOU MEDICAL UNIV
Preparation method of Tlr7a-induced enhanced DC-NK cells
InactiveCN106148281AEnhance killing activityLower requirementBlood/immune system cellsCell culture active agentsNatural Killer Cell Inhibitory ReceptorsLymphocyte
The invention provides a preparation method of Tlr7a-induced enhanced DC-NK cells. According to the technical scheme, the DC-NK cells are high-activity lymphocytes obtained by being separated from peripheral blood of a patient, adding a series of cell factors into an in-vitro culture system and conducting Tlr7a stimulation, the DC-NK cells are massively amplified and activated through the culture method, therefore, the tumor-cytotoxicity capacity of the DC-NK cells is improved, and the DC-NK cells reach the level of being applied to clinical tumor treatment. Compared with DC-NK cells prepared through a common method, the DC-NK cells prepared through the method have the advantage that the killing effect is significant and obviously higher than that of the DC-NK cells cultured through the conventional method. According to the method, a large quantity of DC-NK cells which are safe in application and higher in killing activity can be obtained under the in-vitro culture condition, and meanwhile the advantages that the preparation cost is low, the processes are simple, the conditions are easy to control, the requirements on equipment are low, and large-scale production is easy are achieved.
Owner:SHENZHEN HORNETCORN BIOTECH
A kind of truffle tartary buckwheat health wine and preparation method thereof
ActiveCN104673610BGood effectImprove nutrition and health valueAlcoholic beverage preparationDiseaseBran
Owner:云南谷冠生物科技有限公司
A method for stimulating the efficient proliferation of peripheral blood γδt cells in vitro and its application
ActiveCN105112370BIntact Antitumor CytotoxicityMammal material medical ingredientsBlood/immune system cellsIn vitro stimulationAntiendomysial antibodies
Owner:杭州朔溪生物医药有限公司
Preparation method for tumor antigen targeting DC cells
InactiveCN105483084ARich varietyEfficient intakeMammal material medical ingredientsBlood/immune system cellsFc(alpha) receptorFc receptor
The invention relates to a preparation method for tumor antigen targeting DC cells. By means of the characteristic that an antibody can be combined with a tumor antigen and a DC cell surface FC receptor, the DC cells can specifically take in tumor cell debris through the antibody, so that the tumor cell specific antigen can be taken in and presented. Compared with a method for directly incubating DC cells and tumor cell lysates together, the preparation method for the tumor antigen targeting DC cells has the specificity for taking in the tumor cell antigen and is higher in efficiency, and therefore more and stronger tumor cytotoxicity lymphocytes.
Owner:英普乐孚生物技术(上海)有限公司
A kind of preparation method of effective part of Dendrobium officinale
ActiveCN104258106BOvercome the shortcoming of extremely low extraction rate of fat-soluble active ingredientsImprove utilization efficiencyAntinoxious agentsAntineoplastic agentsHigh concentrationBULK ACTIVE INGREDIENT
The invention discloses a preparation method of an effective part of dendrobium officinale. The method comprises steps as follows: firstly, extracting fat-soluble extracts represented by bibenzyl from the dendrobium officinale with a high-concentration alcohol-water system, refining the extracts with a macroporous resin method to obtain a total bibenzyl effective part with the bibenzyl content higher than 50%, and preparing dregs of the extracts into dendrobium officinale total polysaccharides with water extraction and alcohol precipitation methods; drying and evenly mixing the total bibenzyl effective part and the dendrobium officinale total polysaccharides obtained in two steps to obtain a dendrobium officinale total effective part extract. According to the method, the defect of the extremely low extraction rate of dendrobium officinale fat-soluble active ingredients represented by the bibenzyl with traditional methods such as a water decoction method, a tea making method and the like is overcome, the utilization efficiency of the effective part of the dendrobium officinale is improved substantially, pharmacological anti-oxidation animal experiments and anti-tumor cytotoxicity experiments prove that the activity of the effective part is significantly higher than that of traditional aqueous extracts, and the effective part has the characteristics of high extraction rate and high activity.
Owner:NINGBO FENGKANG BIOLOGICAL TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com